Efficacy of Dexamethasone for the Treatment of COVID-19 Infection: A Perspective Review

被引:9
作者
Wahab, Shadma [1 ]
Ahmad, Irfan [2 ]
Usmani, Shazia [3 ]
Ahmad, Md. Parwez [4 ]
机构
[1] King Khalid Univ, Coll Pharm, Abha, Saudi Arabia
[2] King Khalid Univ, Coll Appl Med Sci, Abha, Saudi Arabia
[3] Integral Univ, Fac Pharm, Lucknow, India
[4] Mald Natl Univ, Sch Med, Dept Pharmacol, Male, Maldives
关键词
Dexamethasone; covid-19; pandemic; treatment; cytokine storm; SARS-CoV-2; infection; MECHANISMS;
D O I
10.2174/1567201817666201006144008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The current COVID-19 pandemic has provoked the urgent requirement to search for effective treatments since the implications are so huge globally as compared to the earlier pan-demics. Momentarily, there has been no effective medicine for SARS-CoV-2 infection, and suppor-tive care tends to be the most effective approach to treat COVID-19 patients. The rapidly growing awareness of SARS-CoV-2 virology offers a large number of possible drug targets. The World Health Organisation (WHO) is steadily updating the treatment protocol for COVID-19 based on the recent clinical trials. In the present review, we have summarised the possible mode of action, clinical evidence, consequences of dexamethasone as the therapeutic agent against Covid-19. Cur-rently, many corticosteroids are being tested in ongoing randomised trials. Dexamethasone could come as the life-saving drug. Dexamethasone drug looks useful only in those patients who are al -ready in a critical state. We might allow dexamethasone as a fascinating shot, if the drug proves to be clinically favourable for long-term health effects of Covid-19 recovered patients. It is common -ly accepted to reinforce approved drugs in the fight against newly emerging diseases such as COVID-19 as these drugs have established pharmacokinetic profiles and protection. The current fo-cus should be on the development of novel proven therapeutics along with vaccines. There is a need for high quality, more extensive, rapid and collaborative randomized controlled trials with more control groups.
引用
收藏
页码:546 / 554
页数:9
相关论文
共 38 条
[1]  
[Anonymous], 2009, WHO TECHN REP SER, V954
[2]   16-METHYLATED STEROIDS .2. 16-ALPHA-METHYL ANALOGS OF CORTISONE, A NEW GROUP OF ANTI-INFLAMMATORY STEROIDS - 9ALPHA-HALO DERIVATIVES [J].
ARTH, GE ;
FRIED, J ;
JOHNSTON, DBR ;
HOFF, DR ;
SARETT, LH ;
SILBER, RH ;
STOERK, HC ;
WINTER, CA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1958, 80 (12) :3161-3163
[3]  
Becker Daniel E, 2013, Anesth Prog, V60, P25, DOI 10.2344/0003-3006-60.1.25
[4]  
Bingham Z, 2016, DRUG DISCOVERY MED C, P28
[5]   MACROCORTIN - A POLYPEPTIDE CAUSING THE ANTI-PHOSPHOLIPASE EFFECT OF GLUCOCORTICOIDS [J].
BLACKWELL, GJ ;
CARNUCCIO, R ;
DIROSA, M ;
FLOWER, RJ ;
PARENTE, L ;
PERSICO, P .
NATURE, 1980, 287 (5778) :147-149
[6]   Patients with rheumatoid arthritis exposed to COVID-19: A family cluster report [J].
Cai, Shaozhe ;
Sun, Wei ;
Zhong, Jixin ;
Dong, Lingli .
MODERN RHEUMATOLOGY, 2021, 31 (02) :514-517
[7]  
Carlos W Graham, 2020, AM J RESP CRIT CARE, V201, pP7, DOI [10.1164/rccm.2014P7, DOI 10.1164/RCCM.202008-3265OC]
[8]  
Ciobotaru OR, 2019, REV CHIM-BUCHAREST, V70, P843
[9]   Current concepts - Corticosteroid insufficiency in acutely ill patients [J].
Cooper, MS ;
Stewart, PM .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (08) :727-734
[10]   Bat Coronaviruses in China [J].
Fan, Yi ;
Zhao, Kai ;
Shi, Zheng-Li ;
Zhou, Peng .
VIRUSES-BASEL, 2019, 11 (03)